Records containing: Schizophrenia

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

• CLINICAL_TRIALS study record update · 2014-07-11
  The Effectiveness of The Meta-cognitive Training Among Chronic Schizophrenia Patients Treated Within Community Support Groups in Poland.
• CLINICAL_TRIALS study record update · 2014-07-08
  N-methyl-D-aspartate (NMDA) Enhancers' Benefit to Schizophrenia Treatment
• CLINICAL_TRIALS study record update · 2014-07-03
  Varenicline and Smoking Cessation in Schizophrenia
• CLINICAL_TRIALS study record update · 2014-07-02
  Web-Based Weight Management for Individuals With Mental Illness
• CLINICAL_TRIALS study record update · 2014-06-30
  Schizophrenia Patient and Family Continuity of Care
• Organize your saved records without ads with Plus.
• CLINICAL_TRIALS study record update · 2014-06-27
  A Multicentric, Open Label, Randomized, Balanced, Two Treatment, Three Period, Three Sequence, Crossover, Multiple Dose, Steady State Bioequivalence Study of Asenapine Sublingual Tablets, 10 mg Manufactured by AMNEAL PHARMACEUTICALS, USA With Reference Product SAPHRIS® (Asenapine) Sublingual Tablets, 10 mg Manufactured by Catalent UK Swindon Zydis Ltd., Blagrove, Swindon, Wiltshire, SN5 8RU, UK; Distributed by Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, 08889, USA in Adult Human Male & Female Patients Under Fasting Condition.
• CLINICAL_TRIALS study record update · 2014-06-25
  An Open-label, Prospective, Randomized and Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug
• CLINICAL_TRIALS study record update · 2014-06-24
  Randomized, Double-blind, Placebo-controlled add-on Trial of the Safety and Efficacy of RO4917838 in Outpatients on Select Atypical Antipsychotics With Prominent Negative or Disorganized Thought Symptoms
• CLINICAL_TRIALS study record update · 2014-06-24
  A Long-Term, Open-Label Study of Flexibly Dosed Paliperidone Palmitate Long-Acting Intramuscular Injection in Japanese Patients With Schizophrenia
• CLINICAL_TRIALS study record update · 2014-06-20
  A Randomized Double-blind Placebo-controlled Parallel Group Study Evaluating Paliperidone Palmitate in the Prevention of Recurrence in Patients With Schizophrenia. Placebo Consists of 20% Intralipid (200 mg/mL) Injectable Emulsion.
• CLINICAL_TRIALS study record update · 2014-06-19
  Cognitive Training to Improve Work Outcomes in Severe Mental Illness
• CLINICAL_TRIALS study record update · 2014-06-17
  An Exploratory Study to Measure and Contrast Implicit and Explicit Learning Performance in Patients With Stable Schizophrenia and Young and Elderly Healthy Subjects
• CLINICAL_TRIALS study record update · 2014-06-16
  Medication Adherence in Schizophrenia: Development of a CBT-Based Intervention
• CLINICAL_TRIALS study record update · 2014-06-16
  An Open Multicentric Randomized Clinical Trial Assessing the Impact of Motivational Interviewing on Cannabis Consumption in Patients With Psychiatric Disease
• CLINICAL_TRIALS study record update · 2014-06-12
  A Placebo Controlled Trial of Glycine Added to Clozapine in Schizophrenia
• CLINICAL_TRIALS study record update · 2014-06-10
  Enhancing the Prospective Prediction of Psychosis
• CLINICAL_TRIALS study record update · 2014-06-06
  Prolonged-release Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia: a Randomized Clinical Trial
• CLINICAL_TRIALS study record update · 2014-06-06
  Effectiveness of Atypical Vs Conventional Antipsychotics
• CLINICAL_TRIALS study record update · 2014-06-06
  Aripiprazole Treatment of Prodromal Patients
• CLINICAL_TRIALS study record update · 2014-06-06
  Paliperidone Extended Release Tablets for the Prevention of Relapse in Subjects With Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
• CLINICAL_TRIALS study record update · 2014-06-03
  An Open-Label Prospective, Non-Comparative Study To Explore The Tolerability, Safety and Effectiveness Upon Transition to Paliperidone Slow-Release Tablet in Schizophrenic Patients
• CLINICAL_TRIALS study record update · 2014-05-30
  First-in-Patient Study to Assess the Safety and Tolerability and to Explore the Potential Therapeutic Efficacy of a Novel Glutamate Modulator as Monotherapy and as Add-On Therapy in Patients With Schizophrenia
• CLINICAL_TRIALS study record update · 2014-05-29
  A Phase 3 Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, 12-week, Forced-dose Titration Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 40mg, 100mg, or 160mg as Adjunctive Treatment to Established Maintenance Doses of Antipsychotic Medications on Negative Symptoms in Clinically Stable Adults Who Have Persistent Predominant Negative Symptoms of Schizophrenia
• CLINICAL_TRIALS study record update · 2014-05-29
  A Phase 3, Long-term, Open-label, Multicenter, 52-week, Flexible-dose Safety Study of SPD489 as Adjunctive Treatment to Established Maintenance Doses of Antipsychotic Medications on Negative Symptoms in Clinically Stable Adults Who Have Persistent Predominant Negative Symptoms of Schizophrenia
• CLINICAL_TRIALS study record update · 2014-05-29
  A Phase 3 Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, 26-week, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 Low Dose Range (40mg, 80mg, 100mg) and High Dose Range (120mg, 140mg, 160mg) as Adjunctive Treatment to Established Maintenance Doses of Antipsychotic Medications on Negative Symptoms in Clinically Stable Adults Who Have Persistent Predominant Negative Symptoms of Schizophrenia